Stockreport

Rubius Therapeutics Provides Update on Clinical Trial Progress for its Lead Oncology Product Candidate RTX-240 and Announces Planned Leadership Transition

Rubius Therapeutics, Inc.  (RUBY) 
Last rubius therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report
PDF CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering [Read more]